Compounds which prevent neuronal cell death and uses thereof
AssigneeThe Trustees of Columbia University in the City of New York
InventorCarol M. Troy
Life of this patent
Estimating the term…
Abstract
The present invention provides for a compound having the structure: (AA1)n-Cys-(AA2)m wherein n=0,1,2,3,4 or 5 and m=0,1,2,3,4 or 5, provided the sum of (n+m) is greater than or equal to two and less than or equal to five, if n=1, (AA1)n=Ala-, if n=2, (AA1)n=Gln-Ala-, if n≧3, (AA1)n=(Xaa)p-Gln-Ala-, and Xaa=any amino acid and wherein if n=n3, p=1, if n=4, p=2, if n=5, p=3, if m=1, (AA2)m=-Arg, if m=2, (AA2)m=-Arg-Gly, if m≧3, (AA2)m=-Arg-Gly-(Xaa)q, wherein if m=3, q=1, if m=4, q=2, if m=5, q=3. The present invention provides for a method of inhibiting cell death and a method for alleviating symptoms of a neurodegenerative disorder in a subject.
Claims11
A composition comprising a pharmaceutically acceptable carrier and a non-cyclic compound that inhibits programmed cell death, the compound consisting of the structure:
- (AA1)n-Cys-(AA2)m
- wherein
- (a) n and m are independently 0, 1, 2, 3, 4 or 5, provided that 2≦(n+m)≦5;
- (b) if n=1, (AA1)n=Ala-;
- (c) if n=2, (AA1)n=Gln-Ala-;
- (d) if n≧3, (AA1)n=(Xaa)p-Gln-Ala-, wherein Xaa is any amino acid, and (i) if n=3, p=1, (ii) if n=4, p=2, and (iii) if n=5, p=3;
- (e) if m=1, (AA2)m=-Arg;
- (f) if m=2, (AA2)m=-Arg-Gly;
- and
- (g) if m=3, (AA2)m=-Arg-Gly-(Xaa)q, wherein (i) if m=3, q=1, (ii) if m=4, q=2, and (iii) if m=5, q=3.
A composition comprising a pharmaceutically acceptable carrier and a non-cyclic compound that inhibits programmed cell death, the compound consisting of the structure:
- (AA1)n-Cys-(AA2)m
- wherein
- (a) n and m are independently 0, 1, 2 or 3, provided that 2≦(n+m)≦5;
- (b) if n=1, (AA1)n=Ala-;
- (c) if n=2, (AA1)n=Gln-Ala-;
- (d) if n=3, (AA1)n=(Xaa)p-Gln-Ala-, wherein Xaa is any amino acid, and if n=3, p=1;
- (e) if m=1, (AA2)m=-Arg;
- (f) if m=2, (AA2)m=-Arg-Gly;
- and
- (g) if m=3, (AA2)m=-Arg-Gly-(Xaa)q, wherein if m=3, q=1.
A pharmaceutically acceptable carrier and a non-cyclic compound that inhibits programmed cell death, the compound consisting of the structure:
- (AA1)n-Cys-(AA2)m
- wherein
- (a) n=2 or 3 and m=0, 1, 2 or 3, provided that 2≦(n+m)≦5;
- (b) if n=2, (AA1)n=Gln-Ala-;
- (c) if n=3, (AA1)n=(Xaa)p-Gln-Ala-, wherein Xaa is any amino acid, and if n=3, p=1;
- (d) if m=1, (AA2)m=-Arg;
- (e) if m=2, (AA2)m=-Arg-Gly;
- and
- (f) if m=3, (AA2)m=-Arg-Gly-(Xaa)q, wherein if m=3, q=1.
Dependencies are inferred from the claim text.